- Home
- RBOT vs APLT Comparison
RBOT vs APLT Comparison
Compare RBOT & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | APLT |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 18.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | RBOT | APLT |
|---|---|---|
| Price | $1.88 | $0.10 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.00 | $1.25 |
| AVG Volume (30 Days) | 164.0K | ★ 10.3M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.83 | $0.10 |
| 52 Week High | $18.97 | $1.50 |
Technical Indicators
Market Signals| Indicator | RBOT | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 25.27 | 25.07 |
| Support Level | $2.16 | $0.10 |
| Resistance Level | $2.33 | $0.12 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 5.14 | 4.78 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.